Suicide Plus Immune Gene Therapy for Advanced Melanoma

Exclusion Criteria

• •Patients with uncontrolled cardiovascular disease
• •Patients with uncontrolled respiratory disease.
• •Patients with uncontrolled immune disease.
• •Patients with glucocorticoids or immunosuppressive drugs or agents with immunomodulatory activity (except non-steroidal anti-inflammatory agents) up to 2 weeks before treatment.
• •Patients performing other experimental therapies.
• •Patients who are pregnant or breastfeeding.
• •Patients undergoing concurrent chemotherapy or radiation therapy.
• •Uncontrolled diabetes.
• •Patients with active diagnosis of other malignant neoplasms.
• •HIV-positive patients.
• •Uncontrolled thyroid abnormality.
• •Patients with significant medical morbidity.
• •Patients with a history of allergic reactions to chemicals or similar to those used in this study.
• •Metastasis in the central nervous system.
• •Laboratory eligibility criteria excluded:
• •* Hemoglobin: \<8 g / dL, leukocytes: \<3,000 / mm3, platelets: \<100,000 / mm3, neutrophils: \<1000 / mm3, hematocrit: \<25%. bilirubin\> 2.0 mg / dL, GOT or GPT: 2.5 times\> than normal upper institutional limit (ULN), alkaline phosphatase: 2 times\> ULN, creatinine\> 2.0 mg / dL, creatinine clearence : \<60 ml / min / 1.73 m2.